These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33509057)

  • 1.
    Jahangiri R; Mosaffa F; Emami Razavi A; Teimoori-Toolabi L; Jamialahmadi K
    J Oncol Pharm Pract; 2022 Mar; 28(2):310-325. PubMed ID: 33509057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
    Alkner S; Bendahl P; Grabau D; Malmström P; Fernö M; Rydén L;
    Ann Oncol; 2013 May; 24(5):1244-52. PubMed ID: 23230135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered DNA methyltransferases promoter methylation and mRNA expression are associated with tamoxifen response in breast tumors.
    Jahangiri R; Mosaffa F; Emami Razavi A; Teimoori-Toolabi L; Jamialahmadi K
    J Cell Physiol; 2018 Sep; 233(9):7305-7319. PubMed ID: 29574992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
    Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
    Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
    Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
    O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
    Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.
    Weiner M; Skoog L; Fornander T; Nordenskjöld B; Sgroi DC; Stål O
    Ann Oncol; 2013 Aug; 24(8):1994-9. PubMed ID: 23670096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
    Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
    Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
    Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
    Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
    PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.
    Hurtado A; Holmes KA; Geistlinger TR; Hutcheson IR; Nicholson RI; Brown M; Jiang J; Howat WJ; Ali S; Carroll JS
    Nature; 2008 Dec; 456(7222):663-6. PubMed ID: 19005469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIB1 is a predictive factor for tamoxifen response in premenopausal women.
    Alkner S; Bendahl PO; Grabau D; Lövgren K; Stål O; Rydén L; Fernö M;
    Ann Oncol; 2010 Feb; 21(2):238-244. PubMed ID: 19628566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
    BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between the expression of amplified in breast cancer 1、androgen receptor and tamoxifen resistance in breast cancer].
    Liu N; Meng QX; Wang GS
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(20):1553-1559. PubMed ID: 37246005
    [No Abstract]   [Full Text] [Related]  

  • 19. PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients.
    Jahangiri R; Mosaffa F; Gharib M; Emami Razavi AN; Abdirad A; Jamialahmadi K
    Tissue Cell; 2018 Jun; 52():135-142. PubMed ID: 29857823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
    Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
    Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.